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Background
Our recent data have shown that a subset of CD8+BTLA+
was the strongest predictive biomarker of response to
adoptive T cell therapy using tumor-infiltrating lympho-
cytes. BTLA, B-and-T lymphocyte attenuator, is known as
an inhibitory molecule in different immune cells. Its cyto-
plasmic region contains three motifs (Grb2, ITIM, and
ITSM). ITIM and ITSM are inhibitory motifs that sup-
press T cell function upon ligation of the BTLA ligand,
HVEM (Herpes virus entry mediator). However, the phy-
siological function of Grb2 motif, known to interact with
p85 PI3K, remains unclear. The aim of this study was to
investigate the role of the Grb2 motif of BTLA in CD8+
TIL and murine CD8+ T cells.
Methods
To dissect the signaling pathway of BTLA’s motifs, we
generated retroviral vectors containing BTLA and its
mutants by substitution of tyrosine (Y) for phenylalanine
(F) in either the Grb2 motif (ΔGrb2) or ITIM and ITSM
(Δ ITIM and ITSM). BTLA and its mutants were overex-
pressed in either CD8+BTLA-human TIL or BTLA-/-
mouse T cells to uncover BTLA downstream signaling
pathways and in vivo anti-tumor effect following TIL
transfer.
Results
AKT and MAPK pathway was significantly suppressed in
the Grb2 mutant upon HVEM ligation. Greater prolifera-
tion was pronounced in ITIM and ITSM mutant mouse
T cells when stimulated with DCs pulsed with the cognate
peptide, while less proliferation was observed when Grb2
was inactivated. NOD scid gamma (NSG) mice were
engrafted human derived melanoma and TIL overexpres-
sing BTLA mutants for the investigation of an anti-tumor
effect. ITIM and ITSM mutant TIL exhibited better tumor
burden control and were present at higher frequency in
peripheral blood following adoptive transfer.
Conclusions
Our study revealed that the Grb2 motif provided a positive
signal that favors anti-tumor responses. Therefore, the
strategy to inactivate ITSM and ITSM may enhance per-
sistence following infusion and resulting in mediating
tumor control.
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